Literature DB >> 6875810

The pharmacokinetics of furazlocillin in healthy humans.

P H Hinderling, U Gundert-Remy, D Förster, W Gau.   

Abstract

The pharmacokinetics of the novel acylureidopenicillin furazlocillin, 6-[D-2-(3-furfurylidenamino-2-oxo-imidazolidine-1-carboxamido)-2 -(4-hydroxyphenyl)-acetamido]-penicillanic acid and of its penicilloic acid derivative were investigated in five healthy male volunteers after intravenous administration of 2 and 4 g dosages. The volunteers were either in a lying or sitting position throughout the duration of the studies. The concentrations of the drug in plasma and urine were measured by two different methods in parallel: a microbiological assay and a newly developed high pressure liquid chromatography method. The latter method was also applicable for quantitation of the penicilloic acid derivative in these biological fluids. The drug's plasma protein binding (66%) and apparent red cell-plasma partition coefficient (0.055) were concentration independent. The pharmacokinetics of the drug were first order only at the lower dose level. The apparent half lives of three distinguishable phases were, respectively, 4(t1/21), 18 (t1/22), and 64 (t1/2z) min. The total and renal clearances of the drug were, respectively, 303 and 79 ml/min. The latter value implied tubular secretion of the drug. Graphical and digital computer analyses of the data were performed with a linear three compartment body model. Small but consistent deviations from linear kinetics caused by the nonrenal elimination route were observed after administration of the higher dose (4 g). In contrast, renal elimination showed no such dose dependency and was first order. The disposition kinetics of furazlocillin were body position independent. The penicilloic acid derivative of furazlocillin was found in plasma and urine in all the five subjects tested. The percentage of the dose excreted renally as the derivative amounted, respectively, to 5.2 and 7.0% after the lower and higher dosage of furazlocillin, with significant inter- and intrasubject variability. The renal clearance of the derivative was 41 ml/min.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6875810     DOI: 10.1007/bf01061765

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  36 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

3.  Drug elimination and apparent volume of distribution in multicompartment systems.

Authors:  M Gibaldi; D Perrier
Journal:  J Pharm Sci       Date:  1972-06       Impact factor: 3.534

4.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

5.  Effect of different degrees of tilt on cardiac output, heart rate, and blood pressure in normal man.

Authors:  J Tuckman; J Shillingford
Journal:  Br Heart J       Date:  1966-01

6.  [Chemical aspects of penicillin allergy. The direct penicilloylation of epsilon-amino groups by penicillin at pH 7.4].

Authors:  C H Schneider; A L de Weck
Journal:  Helv Chim Acta       Date:  1966-07-11       Impact factor: 2.164

7.  Azlocillin: in vitro studies of a new semisynthetic penicillin.

Authors:  D Stewart; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

8.  [Pharmacokinetics of azlocillin, a new semisynthetic, wide-spectrum antibiotic (author's transl)].

Authors:  K Wirth; M Schomerus; J H Hengstmann
Journal:  Infection       Date:  1976       Impact factor: 3.553

9.  Protein binding and erythrocyte partitioning of the antirheumatic proquazone.

Authors:  A Roos; P H Hinderling
Journal:  J Pharm Sci       Date:  1981-03       Impact factor: 3.534

10.  Azlocillin and mezlocillin: new ureido penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

View more
  3 in total

1.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

2.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.

Authors:  W R Gillespie; P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

Review 3.  Influence of posture on pharmacokinetics.

Authors:  Christian Queckenberg; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-10-21       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.